With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots
Debut deal for $300M fund brings in royalty streams for Paratek’s Nuzyra
The debut deal for CBC’s new $300 million fund brings in royalty streams for Paratek’s anti-infective drug Nuzyra.
Jan 4, 2021 | 10:12 PM GMT
CBC Group believes the maturing market for innovative products in Greater China represents an opportunity sufficient to support its launch